Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
第一作者:
Florian,Guisier
第一单位:
Rouen University Hospital, Pulmonology, Thoracic Oncology and Respiratory Intensive Care Unit & CIC CRB INSERM 1404, Rouen, France. Electronic address: florian.guisier@chu-rouen.fr.
作者:
医学主题词
老年人(Aged);女(雌)性(Female);人类(Humans);免疫疗法(Immunotherapy);肺肿瘤(Lung Neoplasms);男(雄)性(Male);突变(Mutation);前瞻性研究(Prospective Studies);原癌基因蛋白质B-raf(Proto-Oncogene Proteins B-raf);原癌基因蛋白质c-ret(Proto-Oncogene Proteins c-ret);回顾性研究(Retrospective Studies)
DOI
10.1016/j.jtho.2019.12.129
PMID
31945494
发布时间
2021-01-06
- 浏览3
Journal of thoracic oncology
628-636页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



